Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Nipah virus is an emerging zoonotic infection that can cause severe respiratory illness and encephalitis. According to the World Health Organization, cases were first reported in 1998 and have since been documented in Bangladesh, India, Malaysia, the Philippines, and Singapore, with an estimated case fatality rate of 40%–75%. Zoonotic disease transmission remains a key epidemiological concern. As per the Nipah virus Epidemiology Forecast by Expert Market Research, ongoing surveillance is important for assessing the disease burden.
Base Year
Historical Period
Forecast Period

Read more about this report - Request a Free Sample
Expert Market Research's “Nipah Virus Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Nipah virus. It projects the future incidence and prevalence rates of Nipah virus cases across various populations. The study covers age, gender, and type as major determinants of the Nipah virus population. The report highlights patterns in the prevalence of Nipah virus over time and projects future trends based on multiple variables.
The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Nipah virus in the 8 major markets.
Regions Covered
Nipah virus disease is a serious zoonotic infection caused by Nipah virus (NiV), an enveloped RNA virus in the Henipavirus genus. Fruit bats of the Pteropus genus are the natural hosts, and transmission to humans can occur through contact with infected animals, contaminated food, or close contact with an infected person. The disease can range from asymptomatic infection to acute respiratory illness and severe encephalitis. There are no formally recognized clinical “types”; however, Nipah virus infection commonly presents with predominantly respiratory, neurological, or combined manifestations.
|
Parameter |
Insight |
|
Largest Patient Pool |
India |
|
Fastest Growing Country |
India |
|
High-Risk Population |
Healthcare workers, caregivers, household contacts, and people with exposure to infected animals or contaminated food |
|
Key Diagnostic Method |
Real-time polymerase chain reaction (RT-PCR); ELISA may support later-stage or post-infection diagnosis |
|
Major Risk Factor |
Close exposure to infected bats, animals, contaminated food, or infected individuals |
|
Major gap in the market |
Limited availability of specific therapeutics and the need for rapid, high-containment diagnostic capacity |
The Nipah virus epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Nipah virus epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Nipah virus and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
|
Epidemiology Segment |
Key Insights |
|
Diagnosed Prevalent Cases of the Disease |
Nipah virus has a geographically concentrated epidemiological profile, with human outbreaks reported in Bangladesh, India, Malaysia, the Philippines, and Singapore. According to the World Health Organization, Bangladesh has reported outbreaks almost annually since 2001, while India has experienced periodic outbreaks. |
|
Gender-Specific Cases of the Disease |
Gender-specific patterns vary by outbreak and are not sufficient in the provided evidence to establish a consistent sex-based epidemiological trend. In the September 2023 Kerala outbreak, all six confirmed cases were male, according to the World Health Organization. |
|
Age-Specific Cases of the Disease |
The 2023 Kerala outbreak affected individuals aged 9 to 45 years. According to the World Health Organization (2023), all six laboratory-confirmed cases occurred within this age range, demonstrating infections across both pediatric and adult populations. |
|
Ethnicity-Wise Cases of the Disease |
Nipah virus is associated with substantial mortality. As per the World Health Organization (2026), the estimated case fatality rate is 40%–75%, although rates vary between outbreaks according to surveillance and clinical management. |
|
Mortality and Survival Analysis of the Disease |
Nipah virus generally produces localized outbreaks rather than sustained widespread transmission. According to the World Health Organization (2026), India has experienced recurrent but relatively limited outbreaks, with Kerala representing an important area of repeated spillover and surveillance activity. |

Read more about this report - Request a Free Sample
The Nipah virus epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.
|
Country |
Key Insights |
|
United States |
The United States does not represent an established area of community Nipah virus transmission. Epidemiological relevance is primarily associated with preparedness for potential imported infections, particularly through international travel from affected South and Southeast Asian regions, together with surveillance for high-consequence zoonotic diseases. |
|
Germany |
Germany is not identified among countries with established Nipah virus outbreaks. Epidemiological considerations are therefore centered on maintaining surveillance and preparedness for travel-associated or imported infections, particularly because Nipah virus outbreaks remain concentrated in South and Southeast Asia. |
|
France |
France does not have an established history of community Nipah virus outbreaks in the supplied evidence. Epidemiological preparedness is primarily relevant to international travel and the timely recognition of potential imported infections from countries where Nipah virus transmission has been documented. |
|
Italy |
Spain is not identified as a country with established Nipah virus transmission. The epidemiological context is therefore driven primarily by international surveillance, recognition of potential travel-associated infections, and preparedness for the containment of imported cases originating from affected regions. |
|
Spain |
Italy does not represent an established Nipah virus transmission setting based on the supplied evidence. Epidemiological preparedness is relevant to international travel and the capacity to identify and manage potential imported infections associated with exposure in endemic outbreak regions. |
|
United Kingdom |
No travel-associated cases have been reported in the United Kingdom, according to the UK Health Security Agency (2026). Consequently, epidemiological relevance is primarily linked to preparedness, travel-related risk assessment, and rapid management of suspected imported cases. |
|
Japan |
Japan is not identified among countries with reported human Nipah virus outbreaks. The epidemiological landscape is therefore primarily shaped by international surveillance and preparedness for potential imported infections, particularly given the concentration of documented outbreaks in South and Southeast Asia. |
|
India |
India represents a major epidemiological focus for Nipah virus because of recurrent localized outbreaks. According to the World Health Organization (2026), outbreaks have remained relatively limited in scale but have repeatedly occurred in Kerala and other states. In January 2026, two healthcare workers in West Bengal were confirmed with Nipah virus infection, while a further case was confirmed in Kozhikode, Kerala, in June 2026. |
The principal epidemiological gap is the limited availability of rapid diagnostic and disease-specific therapeutic options for Nipah virus infection. Early symptoms can resemble other febrile, respiratory, or neurological illnesses, creating a need for timely laboratory confirmation using RT-PCR and appropriate biosafety infrastructure. India represents the most relevant opportunity among the specified countries because of its recurrent outbreaks and continued need for surveillance and outbreak preparedness. Emerging opportunities include expanded molecular diagnostic capacity, improved contact-tracing systems, infection-control infrastructure, and development of Nipah-specific therapeutics and vaccines.
There is currently no licensed antiviral treatment or approved vaccine specifically for Nipah virus disease. Management therefore centers on early diagnosis, close clinical monitoring, and supportive care, particularly for patients who develop severe respiratory or neurological complications. Treatment may include oxygen therapy, respiratory support or mechanical ventilation, fluid and nutritional management, and treatment of complications such as pneumonia or cerebral edema. Experimental approaches, including monoclonal antibodies and antiviral agents such as remdesivir, remain under development or evaluation, while evidence for ribavirin is inconclusive.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Report Features |
Details |
|
Base Year |
2025 |
|
Historical Period |
2019-2025 |
|
Forecast Period |
2026-2035 |
|
Epidemiology Statistics Provided |
|
|
Segmentation Provided |
|
|
Geographies Covered |
|
Datasheet
One User
USD 2,699
USD 2,429
tax inclusive*
Single User License
One User
USD 4,299
USD 3,869
tax inclusive*
Five User License
Five User
USD 5,799
USD 4,949
tax inclusive*
Corporate License
Unlimited Users
USD 6,999
USD 5,949
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.